Watson Announces New Name -- Actavis -- for Global Operations - Actavis
`
`HOME INVESTORS PRODUCTS ABOUT RESPONSIBILITY NEWS CAREERS SEARCH
`
`News
`
`>
`
`Press Releases
`
`
`
`PRESS RELEASES
`
`MEDIA CONTACTS
`
`MEDIA
`CONTACTS
`David Belian
`+1 (862) 261 8141
`david.belian@actavis.com
`
`Elisabet Hjaltadottir
`+41 79 909 7370
`elisabet.hjaltadottir@actav
`
`Charlie Mayr
`+1 (862) 261 8030
`media.relations@actavis.c
`
`For local media
`contacts in other
`countries, please visit
`the relevant country
`website.
`
`Investor relations:
`Lisa DeFrancesco
`+1 (862) 261 7152
`investor.relations@actavis
`
`Watson Announces New
`Name -- Actavis -- for Global
`Operations
`
`10.31.2012 | Investors
`- Implementing Name Change in 2013 - -
`Redesigned Logo Captures Power of Global
`Combination - - Global Registration of Actavis in
`Place - PARSIPPANY, N.J., Oct. 31, 2012
`/PRNewswire/ -- Watson ...
`
`- Implementing Name Change in 2013 -
`- Redesigned Logo Captures Power of Global Combination -
`- Global Registration of Actavis in Place -
`
`PARSIPPANY, N.J., Oct. 31, 2012 /PRNewswire/ -- Watson
`Pharmaceuticals, Inc. (NYSE: WPI) today announced that it will adopt
`a new global name – Actavis – effective in 2013. The Company said it
`will initiate a multi-year rebranding campaign for its facilities, operations
`and commercial presence, and will transition to trading under a new
`symbol on the New York Stock Exchange in 2013.
`
`"When we announced the proposed acquisition of Actavis in April
`2012, we immediately instituted an extensive and accelerated review
`of our global brand position and naming equities," said Paul Bisaro,
`President and CEO of Watson. "A pioneer at the dawn of the U.S.
`generic industry in 1984, the Watson corporate name was never
`registered globally. As we initiated our global expansion strategy in
`2009, it became clear that we could not establish a single, unified
`market presence under the Watson brand."
`
`"With our expansion into more than 60 commercial markets around the
`world, we recognized the many benefits of uniting our Company under
`one name to all stakeholders – customers, consumers, payers,
`institutions and shareholders and potential shareholders. We initiated
`an extensive review of the name equities within our portfolio, as well as
`assessing the potential of more than 2,000 potential new names. As
`this process progressed, it became clear that one of the many assets
`within the Actavis acquisition was a single name, trademarked and
`protected around the world. It evokes powerful words: action, vision
`and strength, time-honored attributes of both Watson and Actavis.
`Adopting the Actavis name on a global basis, for our generics, brands
`
`http://www.actavis.com/news/news/thomson-reuters/watson-announces-new-name-actavis-for-global[10/6/2014 5:20:01 PM]
`
`1
`
`

`
`Watson Announces New Name -- Actavis -- for Global Operations - Actavis
`
`and biosimilars businesses, was a logical and cost-effective solution."
`
`Watson has also implemented a distinctive redesign of the Actavis
`name, which reflects the history of both Watson and Actavis. The new
`icon in the logo, designed by the leading global identity firm Lippincott,
`speaks to the Company's fast-evolving business, as well as its dynamic
`culture. A close look reveals a "W" shape emerging from a shaded "A,"
`a subtle historical reference to the Watson heritage and acquisition of
`Actavis.
`
`The color stands out in the universe of pharmaceutical industry
`competitors and reflects growth — a fundamental foundation for the
`Company and its future — and a commitment to be an environmentally
`responsible company. The result is a new, powerful and accessible
`visualization that celebrates the Company's emergence as a global
`pharmaceutical leader, and visually defines its focus on growth and
`success in the future.
`
`Watson intends to officially roll-out this identity in 2013. Until that time,
`the Company will continue to trade on the New York Stock Exchange
`under its present symbol – WPI.
`
`Additional resources are available at ww.multivu.com/mnr/58370-
`wats....
`
`About Watson Pharmaceuticals, Inc.
`
`Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global, integrated
`specialty pharmaceutical company focused on developing,
`manufacturing and distributing generic, brand and biosimilar products.
` The Company has global and U.S. headquarters in Parsippany, New
`Jersey, USA, and international headquarters in Zug, Switzerland.
`
`Watson is the world's third-largest generics manufacturer, with more
`than 750 products marketed globally through operations in more than
`60 countries. Watson's global branded pharmaceutical business
`develops and markets products principally in Urology and Women's
`Health, and is committed to developing and marketing biosimilars
`products in Women's Health, Oncology and other therapeutic
`categories. In addition, Watson is the fourth-largest U.S. generic
`pharmaceutical product distributor through its Anda, Inc. business, and
`also develops and out-licenses generic pharmaceutical products
`outside of the U.S. through its Medis third-party business. Watson has
`announced that it will adopt a new global name – Actavis – effective in
`2013.
`
`About LIPPINCOTT
`
`Lippincott is a leading brand strategy and design firm with a 70-year
`heritage crafting authentic stories, memorable experiences and winning
`strategies for the world's most iconic brands. Its expertise spans all
`aspects of brand building including strategy, identity design,
`environmental branding, customer experience management and brand
`activation. The firm uniquely combines business-based strategic
`thinking and creative excellence to solve complex challenges facing
`corporations today as they shape their brands for the future. Recent
`clients include 3M, Delta Air Lines, Hyatt, Infiniti, Samsung, Starbucks
`and Walmart. Lippincott is part of Oliver Wyman, a global professional
`services organization owned by Marsh & McLennan Companies.
`
`Forward-Looking Statement
`
`http://www.actavis.com/news/news/thomson-reuters/watson-announces-new-name-actavis-for-global[10/6/2014 5:20:01 PM]
`
`2
`
`

`
`Watson Announces New Name -- Actavis -- for Global Operations - Actavis
`
`Statements contained in this press release that refer to Watson's
`estimated or anticipated future results or other non-historical facts are
`forward-looking statements that reflect Watson's current perspective of
`existing trends and information as of the date of this release. For
`instance, any statements in this press release concerning prospects
`related to Watson's strategic initiatives, product introductions and
`anticipated financial performance are forward-looking statements. It is
`important to note that Watson's goals and expectations are not
`predictions of actual performance. Watson's performance, at times, will
`differ from its goals and expectations. Actual results may differ
`materially from Watson's current expectations depending upon a
`number of factors affecting Watson's business. These factors include,
`among others, the inherent uncertainty associated with financial
`projections; successful integration of the Actavis acquisition and the
`ability to recognize the anticipated synergies and benefits of the
`Actavis acquisition; the difficulty of predicting the timing and outcome
`of pending or future litigation and government investigations and risks
`that an adverse outcome in such litigation or investigations could
`render Watson liable for substantial damages or penalties; risks that
`resolution of patent infringement litigation through settlement could
`result in investigations or actions by private parties or government
`authorities or agencies; the impact of competitive products and pricing;
`risks related to fluctuations in foreign currency exchange rates; periodic
`dependence on a small number of products for a material source of net
`revenue or income; variability of trade buying patterns; changes in
`generally accepted accounting principles; risks that the carrying values
`of assets may be negatively impacted by future events and
`circumstances; the timing and success of product launches; the
`difficulty of predicting the timing or outcome of product development
`efforts and regulatory agency approvals or actions, if any; risks and
`uncertainties normally incident to the pharmaceutical industry, including
`product liability claims and the availability of product liability insurance
`on reasonable terms; market acceptance of and continued demand for
`Watson's products; difficulties or delays in manufacturing; the
`availability and pricing of third party sourced products and materials;
`successful compliance with governmental regulations applicable to
`Watson's facilities, products and/or businesses; changes in the laws
`and regulations, including Medicare, Medicaid, and similar laws in
`foreign countries affecting, among other things, pricing and
`reimbursement of pharmaceutical products and the settlement of patent
`litigation; and such other risks and uncertainties detailed in Watson's
`periodic public filings with the Securities and Exchange Commission,
`including but not limited to Watson's Annual Report on Form 10-K for
`the year ended December 31, 2011 and Watson's Quarterly Report on
`Form 10-Q for the period June 30, 2012. Except as expressly required
`by law, Watson disclaims any intent or obligation to update these
`forward-looking statements.
`
`
`
`CONTACTS:
`
`Investors:
`Lisa DeFrancesco
`Office: (862) 261-7152
`Mobile: (862) 222-5076
`
`Media:
`Charlie Mayr
`Office: (862) 261-8030
`
`http://www.actavis.com/news/news/thomson-reuters/watson-announces-new-name-actavis-for-global[10/6/2014 5:20:01 PM]
`
`3
`
`

`
`Watson Announces New Name -- Actavis -- for Global Operations - Actavis
`
`Mobile: (862) 222-3528
`
`
`(Logo: ttp://photos.prnewswire.com/p... )
`
`
`
`SOURCE Watson Pharmaceuticals, Inc.
`
`PRIVACY
`
`COMPLIANCE
`
`DISCLAIMER
`
`SITE MAP
`
`COUNTRY WEBSITES
`
`© ACTAVIS 2014
`
`http://www.actavis.com/news/news/thomson-reuters/watson-announces-new-name-actavis-for-global[10/6/2014 5:20:01 PM]
`
`4